Tests OD-07656 and vedolizumab in ulcerative colitis
Tests OD-07656, then vedolizumab, in adults with moderate to severe ulcerative colitis.
Key facts
- Who runs it
- Odyssey Therapeutics, Inc.
- Where
- Auckland, Christchurch, Hamilton, Nelson, and Upper Hutt, New ZealandSee the 5 sitesAlso in 9 other countries, 27 sites
- Trial code
- Registry title
- Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 57 people, planned
- Started
- 2 Jun 2025
- Expected to end
- Nov 2026
- Type of study
- Interventional, 3 groups
- Treatments tested
- OD-07656
- Vedolizumab
- Record updated
- 11 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderately to severely active ulcerative colitis. They must have had an inadequate response, lost response, or could not take at least one earlier ulcerative colitis treatment.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Confirmed ulcerative colitis that is moderately to severely active, as defined by the 3-component Modified Mayo clinic score.
- Earlier treatment
- Must have had an inadequate response, loss of response, or intolerance/medical contraindication to at least one of: oral aminosalicylates, corticosteroids, immunosuppressants, anti-tumor necrosis factor biologic, anti-interleukin 12/23 biologic, Janus kinase inhibitors, or sphingosine-1-phosphate (S1P) modulators.
Main reasons for not taking part
- Crohn's disease or indeterminate colitis
- Extensive colonic resection
- Colostomy or ileostomy
- Uncontrolled primary sclerosing cholangitis
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- The main inclusion criteria include but are not limited to the following:
- Has a confirmed diagnosis of ulcerative colitis (UC)
- Has moderate to severely active UC as defined by the 3-component Modified Mayo clinic score
- Has an inadequate response, loss of response, or intolerance/medical contraindication to at least one of the following therapies: oral aminosalicylates, corticosteroids, immunosuppressants, anti-tumor necrosis factor biologic, anti-interleukin 12/23 biologic, Janus kinase inhibitors, or sphingosine-1-phosphate (S1P) modulators
Who cannot take part
- Has had extensive colonic resection
- Has diagnosis of Crohn's disease or indeterminate colitis
- The main exclusion criteria include but are not limited to the following:
- Has colostomy or ileostomy
- Has uncontrolled primary sclerosing cholangitis
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial is currently available in New Zealand.
Also in 9 other countries, 27 sites
- PCRN AucklandAuckland, New ZealandContact: Study CoordinatorTaking people
- PCRN ChristchurchChristchurch, New ZealandContact: Study CoordinatorTaking people
- PCRN WaikatoHamilton, New ZealandContact: Study CoordinatorTaking people
- PCRN TasmanNelson, New ZealandContact: Study CoordinatorTaking people
- PCRN WellingtonUpper Hutt, New ZealandContact: Study CoordinatorTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the clinical efficacy and safety of OD-07656 in participants with moderately to severely active ulcerative colitis (UC). In addition, the study will evaluate the potential of OD-07656 to enhance the therapeutic benefit of vedolizumab when given after OD-07656.
The 3 groups in the trial
- OD-07656 Dosing Regimen 1Treatment being tested
Open Label, Oral, twice daily dose
Treatment: OD-07656 and Vedolizumab
- OD-07656 Dosing Regimen 2Treatment being tested
Randomized, Oral, twice daily dose
Treatment: OD-07656 and Vedolizumab
- OD-07656 Dosing Regimen 3Treatment being tested
Randomized, Oral, twice daily dose
Treatment: OD-07656 and Vedolizumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2a, Two-Part, Open-Label and Randomized Study to Evaluate the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis
- Plain-language title
- Tests OD-07656 and vedolizumab in ulcerative colitisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT06850727, who can take part
- Record updated
- 11 February 2026